Assistant Professor
Medical Oncology
University of Ottawa, MD
BC Cancer Agency, FRCP(C)
Recent Publications:

•Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi, KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. British Journal of Haematology 135(3):392-4, Nov 2006.
•Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K, Kollmannsberger C. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. American Journal of Hematology. 81(3):210-1, 2006.
•Heng DYC, Chi KN. Prednisone chemotherapy in asymptomatic hormone refractory prostate cancer. The Canadian Journal of Urology; 13(6):3035, 2006.
•Michels JE, Montemurro T, Kollmannsberger C, Murray N, Chi KN. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter? Cancer, 106(5):1041-6, 2006.
•Tinker A, Winquist E, Canil C, Moore M, Murray RN, Chi KN. Cisplatin, gemcitabine and weekly docetaxel for patients with advanced transitional cell cancer (TCC). Am J Clin Oncol, 29(1):3-7, 2006.
•Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Zhang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Current Cancer Drug Targets. 6(6):455-89, 2006.
•Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW. ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. Journal of Clinical Oncology. 25(6):669-74, 2007.
•Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 110(12):2628-39, 2007.
•Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Current Opinion in Supportive & Palliative Care. 2(3):161-6, 2008.
•Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW,  Venner P, Ruether JD, Chi KN, ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 112(11):2377-83, 2008.
•Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD. Androgen-Independent Prostate Cancer: Results from ASCENT, a Double-blinded, Randomized Comparison of DN-101 Plus Docetaxel to Placebo Plus Docetaxel. Cancer. 112(2):326-30, 2008.
•Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Prior to Radical Prostatectomy for Patients with High Risk Localized Prostate Cancer. Journal of Urology, Volume 180, Issue 2, Pg 565-570, 2008.
•Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology. 19(4):746-51, 2008.
•Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E,  Powers J, Walsh W, Tu D, Eisenhauer E. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clinical Cancer Research. 14(3):833-9, 2008.
•Chi KN. Zoubeidi A. Gleave ME. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. [Review] [41 refs] [Journal Article. Review] Expert Opinion on Investigational Drugs. 17(12):1955-62, 2008 Dec.
•Parulekar WR, McKenzie M, Chi KN, Klotz L, Catton C, Brundage M, Ding K, Hiltz A,  Meyer R, Saad F. Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. Current Oncology, Volume 15, Number 4, pg 14-19, 2008.